Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

After hours: March 10 at 4:20:00 PM EDT Loading Chart for EYE ...